» Articles » PMID: 9497367

Proteasome Inhibitors Activate Stress Kinases and Induce Hsp72. Diverse Effects on Apoptosis

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1998 Apr 16
PMID 9497367
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of the major cytosolic protease, proteasome, has been reported to induce programmed cell death in several cell lines, while with other lines, similar inhibition blocked apoptosis triggered by a variety of harmful treatments. To elucidate the mechanism of pro- and antiapoptotic action of proteasome inhibitors, their effects on U937 lymphoid and 293 kidney human tumor cells were tested. Treatment with peptidyl aldehyde MG132 and other proteasome inhibitors led to a steady increase in activity of c-Jun N-terminal kinase, JNK1, which is known to initiate the apoptotic program in response to certain stresses. Dose dependence of MG132-induced JNK activation was parallel with that of apoptosis. Furthermore, inhibition of the JNK signaling pathway strongly suppressed MG132-induced apoptosis. These data indicate that JNK is critical for the cell death caused by proteasome inhibitors. An antiapoptotic action of proteasome inhibitors could be revealed by a short incubation of cells with MG132 followed by its withdrawal. Under these conditions, the major heat shock protein Hsp72 accumulated in cells and caused suppression of JNK activation in response to certain stresses. Accordingly, pretreatment with MG132 reduced JNK-dependent apoptosis caused by heat shock or ethanol, but it was unable to block JNK-independent apoptosis induced by TNFalpha. Therefore, proteasome inhibitors activate JNK, which initiates an apoptotic program, and simultaneously they induce Hsp72, which suppresses JNK-dependent apoptosis. A balance between these two effects might define the fate of cells exposed to the inhibitors.

Citing Articles

A nuclear protein quality control system for elimination of nucleolus-related inclusions.

Brunello L, Polanowska J, Le Tareau L, Maghames C, Georget V, Guette C EMBO J. 2024; 44(3):801-823.

PMID: 39690241 PMC: 11791210. DOI: 10.1038/s44318-024-00333-9.


PSMC5 insufficiency and P320R mutation impair proteasome function.

Yu Z, Carmichael J, Collins G, DAgostino M, Lessard M, Firth H Hum Mol Genet. 2024; 33(17):1506-1523.

PMID: 38776958 PMC: 11336065. DOI: 10.1093/hmg/ddae085.


Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.

Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986514 PMC: 10056051. DOI: 10.3390/ph16030415.


Target Gene Diversity of the Nrf1-MafG Transcription Factor Revealed by a Tethered Heterodimer.

Katsuoka F, Otsuki A, Hatanaka N, Okuyama H, Yamamoto M Mol Cell Biol. 2022; 42(3):e0052021.

PMID: 35129372 PMC: 8929377. DOI: 10.1128/mcb.00520-21.


The Hsp70-Bag3 complex modulates the phosphorylation and nuclear translocation of Hippo pathway protein Yap.

Baldan S, Meriin A, Yaglom J, Alexandrov I, Varelas X, Xiao Z J Cell Sci. 2021; 134(23).

PMID: 34761265 PMC: 8714078. DOI: 10.1242/jcs.259107.